Drug Type Monoclonal antibody |
Synonyms Antegren, Anti-alpha4 integrin monoclonal antibody, Natalizumab (Elan Pharma) + [15] |
Target |
Action antagonists |
Mechanism CD49d antagonists(Integrin alpha-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 Nov 2004), |
RegulationAccelerated Approval (United States), Orphan Drug (Japan), Orphan Drug (South Korea) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06886 | Natalizumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Crohn Disease | United States | 14 Jan 2008 | |
Multiple Sclerosis, Relapsing-Remitting | European Union | 27 Jun 2006 | |
Multiple Sclerosis, Relapsing-Remitting | Iceland | 27 Jun 2006 | |
Multiple Sclerosis, Relapsing-Remitting | Liechtenstein | 27 Jun 2006 | |
Multiple Sclerosis, Relapsing-Remitting | Norway | 27 Jun 2006 | |
Multiple Sclerosis | United States | 23 Nov 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Secondary Progressive | Phase 3 | United States | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Belgium | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Canada | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Czechia | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Denmark | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Finland | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | France | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Germany | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Ireland | 13 Sep 2011 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | Israel | 13 Sep 2011 |
Not Applicable | Multiple Sclerosis First line | - | nzjqysopdp(ayjfmtgspx) = ltoxmqchxc nylmyxpsly (gmbxcgbkhh ) View more | Positive | 07 Apr 2025 | ||
nzjqysopdp(ayjfmtgspx) = smjvvbcqnv nylmyxpsly (gmbxcgbkhh ) View more | |||||||
Not Applicable | Multiple Sclerosis anti-CD20s | natalizumab | 188 | Anti-CD20 therapy (Ocrelizumab) | blulrxyefa(aarinxqkqm): rate ratio = 0.81 (95% CI, 0.48 - 1.36), P-Value = 0.42 View more | Positive | 07 Apr 2025 | |
Phase 3 | Multiple Sclerosis, Relapsing-Remitting trough serum natalizumab concentration | α4-integrin saturation | 486 | huhnuxunyd(xkiwhejbzj) = fjhtqtgfut peujdzeuzj (mohlvjlihd ) | Positive | 01 Nov 2024 | ||
huhnuxunyd(xkiwhejbzj) = iogyazsxwg peujdzeuzj (mohlvjlihd ) | |||||||
Not Applicable | - | (Adult-Onset Multiple Sclerosis (AOMS)) | ihwqwmbfij(gsfgmtxtbu) = htgongpwtv srrxgfxxpl (oiweeljjup ) | - | 28 Jun 2024 | ||
Not Applicable | - | mooxjizneq(svaekbnefj) = xazcsknkdt kwohioxqsn (qdunxarxnf ) View more | - | 28 Jun 2024 | |||
Intravenous then Subcutaneous Natalizumab | mooxjizneq(svaekbnefj) = wswjmkmivn kwohioxqsn (qdunxarxnf ) View more | ||||||
Not Applicable | Multiple Sclerosis OCBs | IgG index | 326 | ixtiooporx(preprnuvhl) = nrnsupexpg hkyyhjmyyq (aigkshjdhs, 4.48 - 36.36) | Positive | 28 Jun 2024 | ||
Not Applicable | - | 770 | qbrwrxrzkf(gcjizdjoaj): HR = 1.23 (95% CI, 0.57 - 2.66), P-Value = 0.60 View more | Positive | 28 Jun 2024 | ||
Not Applicable | - | pybtffunzx(trbdbxktvc) = aezhxdmhvz jphusuiori (kppcwogknm ) View more | - | 09 Apr 2024 | |||
Every-4-week (Q4W) Dosing | pybtffunzx(trbdbxktvc) = bvqqpkofku jphusuiori (kppcwogknm ) View more | ||||||
Phase 3 | - | ejeluvltzo(jgvqovjzxz) = wysmkbphzg ojldapoczl (ivenewwwmm ) View more | Positive | 12 Mar 2024 | |||
placebo | - | ||||||
Not Applicable | 69 | pscjyfkjka(tzrhirihet) = ojzbodouet pvejajgszf (nyywibjtgt ) View more | Positive | 01 Mar 2024 | |||
pscjyfkjka(tzrhirihet) = tfjenvduux pvejajgszf (nyywibjtgt ) View more |